Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells

Active Project Grant Awarded Last action

Award ID
R44DK133008
Recipient
Awarding agency
Obligated
$1,787,251

Award facts

Completion date 86% complete
Place of performance
Madison, WI 53719, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Diabetes represents a growing global health crisis. Despite continuous advancement in medical management of diabetes, achievement of good blood glucose control remains elusive for many patients. Evidence from patients who receive donor pancreas or islet transplants demonstrates that replenishment of pancreatic islets can restore euglycemia. Unfortunately, the relative scarcity of such organs, plus the lifelong burden of immunosuppression required for their maintenance, puts such therapy out of reach for a majority of diabetics. In this proposed project, regenerative medical solutions (RMS) will build upon its success in generating pancreatic islet-like clusters (ILC) from genetically engineered induced pluripotent stem cells (ipsc) to produce a cell-based diabetes therapy that can be manufactured in abundant quantities, and that will not require immunosuppression for graft maintenance. Specifically, RMS will extend its partnership with pluristyx, which has created an ipsc line (iact) with two novel features: 1) the over-expression of 7 immunomodulatory transgenes which enable IT to evade destruction by the host immune system without triggering a "missing self" response; 2) the integration of failsafetm technology, which facilitates the elimination of dividing cells from an engrafted cell population via the administration of the FDA-approved drug ganciclovir. The utility of the failsafetm system for elimination of proliferative cells from ILC grafts was demonstrated in our recently concluded sbir phase i project. In the current proposed project, RMS will work in partnership with the university of wisconsin-madison to demonstrate that ILC produced from iact cells can restore euglycemia in a mouse model of diabetes, and that these ILC can evade rejection by the immune system of humanized mice. Further, RMS will demonstrate the utility of two independent methods of ensuring graft safety in vivo. First, the failsafetm system will be used to control undesired graft outgrowth in vivo while retaining graft function. Second, antibodies developed for cancer immunotherapy will be used to facilitate graft elimination by the immune system of humanized mice. Following completion of the proposed project, extension of RMS's ongoing manufacturing partnership with pluristyx will facilitate seamless transition toward cgmp production of the cell therapy and evaluation in IND-enabling studies.

Transactions

Action Obligated Date
Amendment $872,115
Original award $915,136

Quick answers

Who received award R44DK133008?

R44DK133008 was awarded to Regenerative Medical Solutions Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on March 1, 2022.

How much is award R44DK133008 worth?

$1,787,251 has been obligated on R44DK133008.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login